¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѾÏÇÐȸ Á¦2ȸ AACR(American Association for Cancer Research)-KCA(Korean Cancer Association) Joint Conference on Precision Medicine in Solid Tumors ¹× Á¦24Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö 2 : 2021-11-12

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѾÏÇÐȸ Á¦2ȸ AACR(American Association for Cancer Research)-KCA(Korean Cancer Association) Joint Conference on Precision Medicine in Solid Tumors ¹× Á¦24Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö 2 : 2021-11-12
±³À°ÀÏÀÚ : 2021-11-12
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È­»ó °­ÀÇ) ¹× ¼­¿ï·Ôµ¥È£ÅÚ 2Ãþ Å©¸®½ºÅ»º¼·ë 2°³·ë  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) Á¦2ȸ AACR(American Association for Cancer Research)-KCA(Korean Cancer Association) Joint Conference on Precision Medicine in Solid Tumors ¹× Á¦24Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö 2 
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  
À̸ÞÀÏ : cancer2@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 300,000¿ø      
ºñ°í 1. »çÀüµî·Ï: 1) ȸ¿ø 10¸¸¿ø, 2) ºñȸ¿ø 15¸¸¿ø, 3) ¾÷ü¹×¿¬±¸¼Ò 20¸¸¿ø, 4) Trainee ¹«·á2. ÀϹݵî·Ï: 1) ȸ¿ø 20¸¸¿ø, 2) ºñȸ¿ø 25¸¸¿ø, 3) ¾÷ü¹×¿¬±¸¼Ò 30¸¸¿ø, 4) Trainee 3¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-12 Room A 08:00~08:30 Tumor microenvironment: Challenges and opportunities  °í±Ô¿µ(KAIST) 
È޽Ġ11-12  08:30~08:50 È޽Ġ () 
±³À°½Ã°£ 11-12 Room A 08:50~09:15 Using a cancer dependency map  William C. Hahn(Dana-Farber Cancer Institute, Boston, MA, USA) 
±³À°½Ã°£ 11-12 Room A 09:15~09:40 Creation of tumor assembloids recapitulating epithelial-stromal interaction in human cancers: Role of Foxa1(Forkhead Box A1)-Hedgehog-Bmp axis in tumor plasticity  ½Å±ÙÀ¯(POSTECH) 
±³À°½Ã°£ 11-12 Room A 09:40~10:05 Organoid modeling of lung disease and lung cancer  Carla F. Kim(Boston Children¡¯s Hospital, Boston, MA, USA) 
±³À°½Ã°£ 11-12 Room A 10:05~10:30 The cooperation of YAP(yes-associated protein) and AP-1(activator protein 1) in ductal cell-derived pancreatic cancer development  ÀÓ´ë½Ä(KAIST) 
±³À°½Ã°£ 11-12 Room B 08:50~09:15 Updates and advances in personalized cancer vaccines  Catherine J. Wu(Dana-Farber Cancer Institute, Boston, MA, USA) 
±³À°½Ã°£ 11-12 Room B 09:15~09:40 TCR(t-cell receptor)-seq analysis in anti-PD-1(programmed death-1) treated patients  ½ÅÀÇö(KAIST) 
±³À°½Ã°£ 11-12 Room B 09:40~10:05 Defining the actionable genome  David B. Solit(Memorial Sloan Kettering Cancer Center, New York, NY, USA) 
±³À°½Ã°£ 11-12 Room B 10:05~10:30 Updates in gastric cancer immunogenomics  ÀÌÁö¿¬(¼º±Õ°üÀÇ´ë) 
È޽Ġ11-12  10:30~10:50 È޽Ġ () 
±³À°½Ã°£ 11-12 Room A 10:50~11:15 Acquired resistance to KRAS(kirsten rat sarcoma viral oncogene homolog) G12C inhibition  Andrew J. Aguirre(Dana-Farber Cancer Institute, Boston, MA, USA) 
±³À°½Ã°£ 11-12 Room A 11:15~11:40 Resistance mechanism and overcome strategy to Raf(receptor accessory factor) inhibitor Belvarafenib  ±èÅ¿ø(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 11:40~12:05 To be announced  Kevan Shokat(University of California San Francisco, San Francisco, CA, USA) 
±³À°½Ã°£ 11-12 Room A 12:05~12:30 Novel route to control KRAS(kirsten rat sarcoma viral oncogene homolog)-driven cancers  ±è¼ºÈÆ(¿¬¼¼´ë ¾à´ë) 
±³À°½Ã°£ 11-12 Room B 10:50~11:15 The discovery of context specific paralog dependence in cancer through combinatorial CRISPR(clustered regularly interspaced short palindromic repeats) screens  William R. Sellers(Broad Institute of MIT and Harvard, Cambridge, MA, USA) 
±³À°½Ã°£ 11-12 Room B 11:15~11:40 To be announced  Á¤ÀçÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 11:40~12:05 Accelerating inhibitor discovery to functionally annotate deubiquitinating enzymes  Sarah J. Buhrlage(Dana-Farber Cancer Institute, Boston, MA, USA) 
±³À°½Ã°£ 11-12 Room B 12:05~12:30 Microfabricated assays to investigate tumor microenvironment  Á¤¼®(°í·Á´ë) 
½Ä»ç 11-12  12:30~13:10 ½Ä»ç  () 
±³À°½Ã°£ 11-12 Room A 13:10~13:30 Optimizing clinical outcomes for Asian patients with EGFR(epidermal growth factor receptor) mutation-positive NSCLC(non-small-cell lung carcinoma)  ÀÌÀ±±Ô(°­ºÏ»ï¼ºº´¿ø) 
±³À°½Ã°£ 11-12 Room B 13:10~13:30 Optimizing treatment for HR+(hormone receptor-positive), HER2-(human epidermal growth factor receptor 2-negative) metastatic breast cancer patients  ¼ÕÁÖÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 13:30~13:50 Lung cancer  Á¤Çö¾Ö(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 11-12 Room B 13:30~13:50 Tumor agnostic therapies toward precision medicine era   Á¶º´Ã¶(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 13:50~14:10 Treatment for advanced EGFR(epidermal growth factor receptor) T790M(threonine at amino acid position 790) positive NSCLC(non-small-cell lung carcinoma)  ±èŹÎ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 13:50~14:10 Pancreatic cancer  ÃµÀç°æ(Â÷ÀÇ´ë) 
È޽Ġ11-12  14:10~14:30 È޽Ġ () 
±³À°½Ã°£ 11-12 Room A 14:30~14:50 NCCN(National Comprehensive Cancer Network) clinical practice guideline of adolescent and young adult oncology  ÀÓ¿¬Á¤(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 14:50~15:10 Extracranial germ cell tumors in adolescents and young adults  Çѽ¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 15:10~15:30 Adenocarcinoma in adolescents and young adults  ¾çÈñ¹ü(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 11-12 Room B 14:30~14:50 Recent advance in the development of novel, ive and potent FGFR(fibroblast growth factor receptors) inhibitors  ±èÈñÁØ(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 14:50~15:10 HER2-(human epidermal growth factor receptor 2-negative) targeted therapies - A role beyond breast and gastric cancer  ±è¹Ì¼Ò(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 15:10~15:30 Inhibitors of MET(mesenchymal–epithelial transition) and RET(rearrangement during transfection) in non-small cell lung cancer (NSCLC)  È«¹ÎÈñ(¿¬¼¼ÀÇ´ë) 
È޽Ġ11-12  15:30~15:50 È޽Ġ () 
±³À°½Ã°£ 11-12 Room A 15:50~16:15 Experience of molecular tumor board in sponsor-initiated trial  ±èÁ¤Àº(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 16:15~16:40 Investigator-initiated personalized treatment by molecular tumor board  ±èÁöÇö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-12 Room A 16:40~17:05 Nationwide precision medicine to accelerate targeted cancer therapies  À̼öÇö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 15:50~16:15 RTOG 1119: Phase II randomized study of whole brain radiotherapy/stereotactic radiosurgery with concurrent lapatinib in patients with brain metastases from HER2-positive breast cancer - a collaborative study of NRG Oncology and KROG  ±èÀξÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 16:15~16:40 Result and lesson KROG(Korean Radiation Oncology Group) 08-06 trial  ±è¿ë¹è(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-12 Room B 16:40~17:05 PBT(Proton Beam Radiotherapy) vs RFA(Radiofrequency Ablation) treatment for recurrent hepatocellular carcinoma: A randomized controlled phase 3 non-inferiority APROH trial  ±èÅÂÇö(±¹¸³¾Ï¼¾ÅÍ) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѾȰúÇÐȸ (¿Â¶óÀÎ)ºÎ»ê¾È°úÁöȸ ÇмúÁý´ãȸ(Æó¼â°¢³ì³»Àå°ú ¹é³»Àå) : 2021-11-12
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(À§¿øȸ) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2021-11-12
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 23 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 24 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 30 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 27 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 26 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 17 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 7 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 7 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 14 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 11 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 5 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 17 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 9 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 17 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 12 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷